CY1115597T1 - CANCER DIAGNOSIS AND TREATMENTS, BASED ON THE ODC1 GENOTYPE - Google Patents

CANCER DIAGNOSIS AND TREATMENTS, BASED ON THE ODC1 GENOTYPE

Info

Publication number
CY1115597T1
CY1115597T1 CY20141100779T CY141100779T CY1115597T1 CY 1115597 T1 CY1115597 T1 CY 1115597T1 CY 20141100779 T CY20141100779 T CY 20141100779T CY 141100779 T CY141100779 T CY 141100779T CY 1115597 T1 CY1115597 T1 CY 1115597T1
Authority
CY
Cyprus
Prior art keywords
treatments
survival
cancer diagnosis
treatment
well
Prior art date
Application number
CY20141100779T
Other languages
Greek (el)
Inventor
Eugene Gerner
Jason Zell
Christine Mclaren
Frank Meyskens
Hoda Anton-Culver
Patricia A Thompson
Original Assignee
Arizona Board Of Regents On Behalf Of University Of Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP10775626.4A external-priority patent/EP2430452B1/en
Application filed by Arizona Board Of Regents On Behalf Of University Of Arizona filed Critical Arizona Board Of Regents On Behalf Of University Of Arizona
Publication of CY1115597T1 publication Critical patent/CY1115597T1/en

Links

Landscapes

  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει μεθόδους και κυτία a) για πρόγνωση επιβίωσης ασθενούς με ορθοκολικό καρκίνο, καθώς επίσης της επιβίωσης ασθενών οι οποίοι φέρουν άλλους διηθητικούς καρκίνους όπου κυτταρικός πολλαπλασιασμός και καρκινογένεση συνδέονται, εν μέρει, με υψηλά επίπεδα ODC δραστικότητας και αυξημένα κυτταρικά περιεχόμενα πολυαμινών, και b) για επιλογή των αντίστοιχων επιλογών αγωγής για τέτοιους ασθενείς με βάση την αλληλόμορφη νουκλεοτιδική αλληλουχία ή SNP στη θέση +316 του γονιδίου ΟDC1 προαγωγέα καθώς επίσης μεθόδων αντιμετώπισης καρκίνου, σε κάθε περίπτωση, οι οποίες περιλαμβάνουν τον προσδιορισμό του γονότυπου +316 θέσης ODC1 προαγωγέα, ως ένα μέσο για καθοδήγηση της επιλογής αγωγής.The present invention provides methods and kits a) for predicting the survival of a patient with colorectal cancer, as well as the survival of patients with other invasive cancers where cell proliferation and carcinogenesis are associated, in part, with high levels of ODC activity and increased cellular activity, b) for selection of the corresponding treatment options for such patients based on the nucleotide sequence or SNP at the +316 position of the ODC1 promoter gene as well as methods for the treatment of cardiomyocytes. furnace, in each case, including genotyping 316 position ODC1 promoter, as a means to guide the treatment choice.

CY20141100779T 2009-05-14 2014-09-24 CANCER DIAGNOSIS AND TREATMENTS, BASED ON THE ODC1 GENOTYPE CY1115597T1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21621609A 2009-05-14 2009-05-14
US21768209A 2009-06-03 2009-06-03
US21767909A 2009-06-03 2009-06-03
EP10775626.4A EP2430452B1 (en) 2009-05-14 2010-05-14 Carcinoma diagnosis and treatments, based on odc1 genotype

Publications (1)

Publication Number Publication Date
CY1115597T1 true CY1115597T1 (en) 2017-01-04

Family

ID=58461579

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100779T CY1115597T1 (en) 2009-05-14 2014-09-24 CANCER DIAGNOSIS AND TREATMENTS, BASED ON THE ODC1 GENOTYPE

Country Status (1)

Country Link
CY (1) CY1115597T1 (en)

Similar Documents

Publication Publication Date Title
CY1120423T1 (en) B7-H1 AND PD-1 IN TREATMENT OF KINDARIAN CELL CARCES
Burrell et al. The causes and consequences of genetic heterogeneity in cancer evolution
CY1117445T1 (en) 5-FLUORO-2´-DEOXYURIDINE PHOSPHORAMIDIC PRODUCTS FOR USE IN CANCER TREATMENT
Hildebrandt et al. Pharmacogenomics of platinum-based chemotherapy in NSCLC
CR9315A (en) METHODS AND SYSTEMS FOR DIAGNOSIS, FORECAST AND SELECTION OF THE TREATMENT OF LEUKEMIA
Quante et al. Mutant p53 is a transcriptional co-factor that binds to G-rich regulatory regions of active genes and generates transcriptional plasticity
CY1117722T1 (en) IMPROVED EDUCATION OF MULTIPLE MYELOMA
UY33619A (en) ANALOGS OF SUBSTITUTED NUCLEOTIDES
CY1118562T1 (en) MICES WHICH CREATE PROTECTION COMMITMENTS WHICH INCLUDE STATES VL
NO20066002L (en) Recombinant chimeric adenovirus, its replication-deficient variant, method of isolating the adenovirus, its use in therapy, and method of inhibiting the growth of a cancer cell.
Cheung et al. Genetic variations in esophageal cancer risk and prognosis
MX2013008367A (en) Colon cancer gene expression signatures and methods of use.
CY1119513T1 (en) METHODS AND RECOMMENDATIONS FOR DIAGNOSIS AND TREATMENT OF SECONDARY SELF-DETERMINING DISEASE TREATMENT
Du et al. Associations of polymorphisms in DNA repair genes and MDR1 gene with chemotherapy response and survival of non-small cell lung cancer
Burrell et al. Re-evaluating clonal dominance in cancer evolution
Koensgen et al. Polymorphism of the IL-8 gene and the risk of ovarian cancer
MX2010002965A (en) Improved detection of mage-a expression.
Gharanei et al. RASSF2 methylation is a strong prognostic marker in younger age patients with Ewing sarcoma
CY1120084T1 (en) Oligonucleotide for the regulation of gene expression and their uses
Wilkins et al. MicroRNA-related genetic variants associated with survival of head and neck squamous cell carcinoma
Yoo et al. TERT polymorphism rs2853669 influences on lung cancer risk in the Korean population
BR112022007932A2 (en) METHODS FOR THE TREATMENT OF LEUKEMIA AND USE OF A LEUKEMIC STEM CELL SIGNATURE TO PREDICT CLINICAL SENSITIVITY TO THERAPIES
MX2013004747A (en) Peripheral blood gene markers for early diagnosis of parkinson's disease.
Zhao et al. Polymorphism in one-carbon metabolism pathway affects survival of gastric cancer patients: Large and comprehensive study
CY1115258T1 (en) METHODS AND USES INCLUDING NAV3 GENETIC DERIVATIVES AND DIFFERENT MULTIPLE GENE EXPRESSION